Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
about
AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug dispositionImmunoaffinity LC-MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker.Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.
P2860
Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Utility of free and total targ ...... -opportunities and challenges.
@en
type
label
Utility of free and total targ ...... -opportunities and challenges.
@en
prefLabel
Utility of free and total targ ...... -opportunities and challenges.
@en
P2860
P356
P1476
Utility of free and total targ ...... -opportunities and challenges.
@en
P2093
Thomas McIntosh
Weirong Wang
P2860
P304
P356
10.1002/JCPH.357
P478
55 Suppl 3
P577
2015-03-01T00:00:00Z